Diabetes, Vol 47, Issue 9 1399-1405, Copyright © 1998 by American Diabetes Association

ARTICLES

Long-term survival of segmental pancreas isografts in NOD/Lt mice treated with anti-CD4 and anti-CD8 monoclonal antibodies

PL Mottram, LJ Murray-Segal, W Han, J Maguire, A Stein-Oakley and TE Mandel
Department of Surgery, Royal Melbourne Hospital, Parkville, Victoria, Australia. p.mottram@medicine.unimelb.edu.au

Spontaneously diabetic nonobese diabetic (NOD/Lt) mice were treated with anti-T-cell monoclonal antibodies (mAbs) at the time of grafting with vascularized segmental pancreas isografts. Recipients were either untreated or given anti-CD4 and/or anti-CD8 mAbs (0.5 mg/20-g mouse on each of 4 consecutive days), which reduced target cell levels to <5% of normal. Graft function was monitored by measuring blood glucose (BG) levels. Transplants were removed for histological examination when BG returned to >20 mmol/l for two consecutive readings. Isografts from 3- to 4-week-old prediabetic mice placed in untreated diabetic NOD mice ceased functioning in 9-13 days with a mean survival time (MST) +/- SD of 10 +/- 2. Treatment with anti-CD4 prolonged survival significantly (MST = 61 +/- 35 days, P < 0.05 compared with untreated control mice). Anti-CD8 treatment was less effective, but it still significantly improved graft survival (MST = 24 +/- 9 days, P < 0.05 compared with untreated control mice). Anti-CD8 plus anti-CD4 treatment was highly effective in inhibiting autoimmune destruction of the grafts (MST = 97 +/- 8 days). This clearly demonstrates that transient inactivation of most T-cells with anti-CD4 plus anti-CD8 mAbs effectively controls autoimmune disease in the isograft, despite recovery of CD4 and CD8 T-cells to normal levels. Although insulitis developed in the long-term grafts, insulitis scores did not increase between 33 and 100 days, and none of the mice progressed to IDDM in 100 days. Histology showed a predominantly peri-islet T-cell and macrophage infiltrate with ductal expression of the cytokines interleukin (IL)-4, IL-2, and interferon-gamma. There was little infiltrate or expression of cytokines within the islets. Thus, mAb treatment at the time of grafting allowed isograft survival and prevented progression from insulitis to beta-cell destruction.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. P. Wong, L. Li, J. A. Frelinger, and R. Tisch Early Autoimmune Destruction of Islet Grafts Is Associated with a Restricted Repertoire of IGRP-Specific CD8+ T Cells in Diabetic Nonobese Diabetic Mice J. Immunol., February 1, 2006; 176(3): 1637 - 1644. [Abstract] [Full Text] [PDF]

				D. A. Mahamed, A. Marleau, M. Alnaeeli, B. Singh, X. Zhang, J. M. Penninger, and Y.-T. A. Teng G(-) Anaerobes-Reactive CD4+ T-Cells Trigger RANKL-Mediated Enhanced Alveolar Bone Loss in Diabetic NOD Mice Diabetes, May 1, 2005; 54(5): 1477 - 1486. [Abstract] [Full Text] [PDF]

				B. Nikolic, Y. Takeuchi, I. Leykin, Y. Fudaba, R. N. Smith, and M. Sykes Mixed Hematopoietic Chimerism Allows Cure of Autoimmune Diabetes Through Allogeneic Tolerance and Reversal of Autoimmunity Diabetes, February 1, 2004; 53(2): 376 - 383. [Abstract] [Full Text]

				D. H. Chung, I. M. Belyakov, M. A. Derby, J. Wang, L. F. Boyd, J. A. Berzofsky, and D. H. Margulies Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antibody J. Immunol., July 15, 2001; 167(2): 699 - 707. [Abstract] [Full Text] [PDF]